4.3 Article

Novel drug targets for asthma and COPD: Lessons learned from in vitro and in vivo models

Journal

PULMONARY PHARMACOLOGY & THERAPEUTICS
Volume 29, Issue 2, Pages 181-198

Publisher

ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pupt.2014.05.008

Keywords

Therapeutic targets; Kinase; G-protein coupled receptor; Transient receptor potential channel; Inflammation; Vitamin D

Funding

  1. Medical Research Council (MRC), UK
  2. National Heart & Lung Institute, UK
  3. Australian Postgraduate Award
  4. Stan and Jean Perron PhD Top-Up Scholarship
  5. Wellcome Trust
  6. Imperial College London
  7. MRC
  8. National Health and Medical Research Council, Australia
  9. LAM Australasia Research Alliance (LARA), Australia
  10. Medical Research Council [1252806] Funding Source: researchfish

Ask authors/readers for more resources

Asthma and chronic obstructive pulmonary disease (COPD) are highly prevalent respiratory diseases characterized by airway inflammation, airway obstruction and airway hyperresponsiveness. Whilst current therapies, such as beta-agonists and glucocorticoids, may be effective at reducing symptoms, they do not reduce disease progression. Thus, there is a need to identify new therapeutic targets. In this review, we summarize the potential of novel targets or tools, including anti-inflammatories, phosphodiesterase inhibitors, kinase inhibitors, transient receptor potential channels, vitamin D and protease inhibitors, for the treatment of asthma and COPD. (C) 2014 Published by Elsevier Ltd.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available